End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
25.16 USD | +5.01% |
|
+11.57% | +141.92% |
06-12 | Dianthus Therapeutics Secures US FDA Approval to Launch Phase 2 Study of DNTH103 in Multifocal Motor Neuropathy | MT |
06-12 | Dianthus Therapeutics Gets FDA Clearance for DNTH103 Phase 2 Trial | DJ |
Sales 2024 * | 1.78M 2.45M | Sales 2025 * | 2M 2.75M | Capitalization | 738M 1.01B |
---|---|---|---|---|---|
Net income 2024 * | -63M -86.59M | Net income 2025 * | -88M -121M | EV / Sales 2024 * | 238 x |
Net cash position 2024 * | 314M 431M | Net cash position 2025 * | 518M 713M | EV / Sales 2025 * | 110 x |
P/E ratio 2024 * |
-11.7
x | P/E ratio 2025 * |
-9.9
x | Employees | 53 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.16% |
1 day | +5.01% | ||
1 week | +11.57% | ||
Current month | +16.43% | ||
1 month | +3.58% | ||
3 months | +0.04% | ||
6 months | +221.74% | ||
Current year | +141.92% |
![Extreme 19.845](/images/extremecours_fleche.png)
![Extreme 19.845](/images/extremecours_fleche.png)
![Extreme 10.22](/images/extremecours_fleche.png)
![Extreme 6.58](/images/extremecours_fleche.png)
![Extreme 6.58](/images/extremecours_fleche.png)
![Extreme 6.58](/images/extremecours_fleche.png)
![Extreme 6.58](/images/extremecours_fleche.png)
Date | Price | Change | Volume |
---|---|---|---|
24-06-12 | 25.16 | +5.01% | 204,084 |
24-06-11 | 23.96 | +11.62% | 180,624 |
24-06-10 | 21.46 | +6.63% | 335,467 |
24-06-07 | 20.13 | -3.82% | 122,595 |
24-06-06 | 20.93 | -7.18% | 166,202 |
End-of-day quote Nasdaq, June 11, 2024
More quotes![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+141.92% | 738M | |
+16.93% | 123B | |
+17.01% | 111B | |
-7.23% | 23.63B | |
+3.09% | 22.58B | |
-14.73% | 17.26B | |
-6.79% | 17.6B | |
-37.63% | 17.61B | |
+2.17% | 13.55B | |
+24.42% | 11.34B |
- Stock Market
- Equities
- DNTH Stock